

P L F Giangrande

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/195134/publications.pdf>

Version: 2024-02-01

31
papers

2,225
citations

471509

17
h-index

477307

29
g-index

31
all docs

31
docs citations

31
times ranked

2101
citing authors

#	ARTICLE	IF	CITATIONS
1	European principles of inhibitor management in patients with haemophilia: implications of new treatment options. Orphanet Journal of Rare Diseases, 2020, 15, 219.	2.7	6
2	Long-term safety and efficacy of N8â€œGP in previously treated adults and adolescents with hemophilia A: Final results from pathfinder2. Journal of Thrombosis and Haemostasis, 2020, 18, 5-14.	3.8	18
3	European principles of inhibitor management in patients with haemophilia. Orphanet Journal of Rare Diseases, 2018, 13, 66.	2.7	33
4	Hepatitis C and bleeding disorders in Europe. The Journal of Haemophilia Practice, 2018, 5, 50-65.	0.4	0
5	Low-factor consumption for major surgery in haemophilia B with long-acting recombinant glycoPEGylated factor IX. Haemophilia, 2017, 23, 67-76.	2.1	31
6	Kreuth IV: European consensus proposals for treatment of haemophilia with coagulation factor concentrates. Haemophilia, 2017, 23, 370-375.	2.1	15
7	Guidelines for the management of acute joint bleeds and chronic synovitis in haemophilia. Haemophilia, 2017, 23, 511-520.	2.1	63
8	Clinical evaluation of glycoPEGylated recombinant FVIII: Efficacy and safety in severe haemophilia A. Thrombosis and Haemostasis, 2017, 117, 252-261.	3.4	96
9	Recombinant activated factor VII in the treatment of bleeds and for the prevention of surgery-related bleeding in congenital haemophilia with inhibitors. Blood Reviews, 2015, 29, S9-S18.	5.7	21
10	Kreuth III: European consensus proposals for treatment of haemophilia with coagulation factor concentrates. Haemophilia, 2014, 20, 322-325.	2.1	43
11	The European standards of Haemophilia Centres. Blood Transfusion, 2014, 12 Suppl 3, s525-30.	0.4	12
12	Present and future challenges in the treatment of haemophilia: the patient's perspective. Blood Transfusion, 2013, 11 Suppl 4, s82-5.	0.4	4
13	Porcine factor VIII. Haemophilia, 2012, 18, 305-309.	2.1	31
14	Management of difficult-to-treat inhibitor patients. Haemophilia, 2010, 16, 52-57.	2.1	9
15	Consensus protocol for the use of recombinant activated factor VII [eptacog alfa (activated); NovoSeven [®]] in elective orthopaedic surgery in haemophilic patients with inhibitors. Haemophilia, 2009, 15, 501-508.	2.1	77
16	Pregnancy in women with inherited bleeding disorders. , 2005, , 16-26.		0
17	Haemophilia B: Christmas disease. Expert Opinion on Pharmacotherapy, 2005, 6, 1517-1524.	1.8	38
18	Gene therapy for hemophilia? No. Journal of Thrombosis and Haemostasis, 2004, 2, 1236-1237.	3.8	15

#	ARTICLE	IF	CITATIONS
19	Treatment of patients with haemophilia and inhibitory antibodies. Indian Journal of Pediatrics, 2003, 70, 655-659.	0.8	3
20	Adverse events in the prophylaxis of haemophilia. Haemophilia, 2003, 9, 50-56.	2.1	15
21	Treatment of hemophilia: recombinant factors only? Yes. Journal of Thrombosis and Haemostasis, 2003, 1, 214-215.	3.8	22
22	Viral pharmacovigilance study of haemophiliacs receiving porcine factor VIII. Haemophilia, 2002, 8, 798-801.	2.1	12
23	Safety and efficacy of KOGENATER Bayer in previously untreated patients (PUPs) and minimally treated patients (MTPs). Haemophilia, 2002, 8, 19-22.	2.1	35
24	Fondaparinux (Arixtra): a new anticoagulant. International Journal of Clinical Practice, 2002, 56, 615-7.	1.7	18
25	Treatment of haemophilia in the United Kingdom 1981â€“1996. Haemophilia, 2001, 7, 349-359.	2.1	5
26	Fibrin Sealant Reduces Blood Loss in Total Hip Arthroplasty. HIP International, 1999, 9, 127-132.	1.7	14
27	Evaluation of a novel ELISA screening test for detection of factor VIII inhibitory antibodies in haemophiliacs. International Journal of Laboratory Hematology, 1999, 21, 125-128.	0.2	22
28	Delayed splenic rupture in a haemophiliac. International Journal of Laboratory Hematology, 1999, 21, 215-218.	0.2	6
29	Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nature Medicine, 1997, 3, 212-217.	30.7	1,096
30	Cytotoxic T-cell activity antagonized by naturally occurring HIV-1 Gag variants. Nature, 1994, 369, 403-407.	27.8	438
31	A cross-over pharmacokinetic and thrombogenicity study of a prothrombin complex concentrate and a purified factor IX concentrate. British Journal of Haematology, 1994, 87, 782-788.	2.5	27